Christian Récher
0000-0002-3332-4525
Publication & Citation Trends
Publications
0 total
Phase 1 Study of KITE-222, an Autologous CLL-1–directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cited by 0
Semantic Scholar
A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.
Cited by 0
Semantic Scholar
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia
Cited by 0
Semantic Scholar
MRD is a new therapeutic target in AML.
Cited by 0
Semantic Scholar
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study
Cited by 0
Semantic Scholar
Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study OA
Cited by 41
Semantic Scholar
Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial
Cited by 3
Semantic Scholar
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia—A FILO Study
Cited by 0
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(603)
Chronic Myeloid Leukemia Treatments
(176)
Cancer, Lipids, and Metabolism
(166)
Ferroptosis and cancer prognosis
(159)
Histone Deacetylase Inhibitors Research
(147)
Affiliations
Délégation Paris 5
Centre National de la Recherche Scientifique
Hudson Institute
The University of Texas MD Anderson Cancer Center
Université Toulouse III - Paul Sabatier